AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 37.5 |
Market Cap | 4.60B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -4.28 |
PE Ratio (ttm) | -8.7 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 39.79 |
Volume | 2,157,335 |
Avg. Volume (20D) | 1,870,409 |
Open | 38.19 |
Previous Close | 38.10 |
Day's Range | 35.83 - 39.29 |
52-Week Range | 15.81 - 39.29 |
Beta | undefined |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...
Analyst Forecast
According to 14 analyst ratings, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is $39, which is an increase of 4.70% from the latest price.
Next Earnings Release
Analysts project revenue of $188.92M, reflecting a 21.84% YoY growth and earnings per share of -0.51, making a -20.31% decrease YoY.
2 months ago · businesswire.com
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board o...
2 months ago · seekingalpha.com
Guardant Health, Inc. (GH) Q3 2024 Earnings Call TranscriptGuardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript
2 months ago · businesswire.com
Guardant Health Named to TIME's List of the Best Inventions of 2024PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shiel...